CASI Pharmaceuticals, Inc. (NASDAQ:CASI)
CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company’s products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland.
CASI Pharmaceuticals, Inc. (NASDAQ:CASI)’s Financial Overview
CASI Pharmaceuticals, Inc. (NASDAQ) surged 20.96% yesterday to close its trading session at $3.52. The company has 1 year Price Target of $7. CASI Pharmaceuticals, Inc. has 52-Week high of $8.89 and 52-Week Low of $1.94. The stock touched its 52-Week High on 8.89 and 52-Week Low on 1.94. The stock traded with the volume of 2.38 Million shares yesterday. The firm shows the market capitalization of $326.69 Million.
CASI Pharmaceuticals, Inc. (NASDAQ) reported its last quarterly earnings on 6/29/2018 where the firm reported its Actual EPS of $-0.07/share against the analyst consensus estimate of $-0.07/share. The difference between the actual and expected EPS is $0 a share with a surprise factor of 0%.
The firm is trading with SMA20 of -11.21 Percent, SMA50 of -38.35 Percent and SMA200 of -38.48 percent. CASI Pharmaceuticals, Inc. has P/S value of 0 while its P/B value stands at 3.63. Similarly, the company has Return on Assets of -28.4 percent, Return on Equity of -31.4 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 1 analysts offering 12-month price forecasts for CASI Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 7.00 and a low estimate of 7.00. The median estimate represents a +98.86% increase from the last price of 3.52.
CASI Pharmaceuticals, Inc. is estimated to report earnings on 11/13/2018. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-0.03.
Sterling Bancorp (NYSE:STL)
Sterling Bancorp is the holding company for Sterling National Bank, a financial services firm. Sterling National Bank provides various banking and financial products and services primarily in New York, New Jersey, and Connecticut. It provides depository and cash management services and a broad portfolio of financing solutions-including working capital lines, accounts receivable and inventory financing, factoring, trade financing, payroll funding and processing, equipment financing, commercial and residential mortgages and mortgage warehouse lines of credit. Sterling Bancorp, formerly known as Provident New York Bancorp, is headquartered in New York.
Sterling Bancorp (NYSE:STL)’s Financial Outlook
The 11 analysts offering 12-month price forecasts for Sterling Bancorp have a median target of 30.00, with a high estimate of 36.00 and a low estimate of 26.00. The median estimate represents a +58.98% increase from the last price of 18.87.
Sterling Bancorp is expected* to report earnings on 10/23/2018 after market close. The report will be for the fiscal Quarter ending Sep 2018. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.51. The reported EPS for the same quarter last year was $0.35.
According to Zacks Investment Research, Sterling Bancorp has a Consensus Recommendation of 1.57. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined -0.47% and closed its last trading session at $18.87. The company has the market capitalization of $4.36 Billion. The stock has 52-week high of $26.5 and 52-Week low of $18.52. The firm touched its 52-Week high on 26.50 and 52-Week low on 18.85. The company has volume of 2.38 Million shares. The company has a total of 231.11 Million shares outstanding.
Sterling Bancorp (NYSE) in the last quarter reported its actual EPS of $0.52/share where the analyst estimated EPS was $0.52/share. The difference between the actual and Estimated EPS is $0. This shows a surprise factor of 0 percent.
The company has YTD performance of -23.29 percent. Beta for Sterling Bancorp stands at 0.97 while its ATR (average true range) is 0.62. The company has Weekly Volatility of 3.59%% and Monthly Volatility of 2.96%%.
Sterling Bancorp has distance from 20-day Simple Moving Average (SMA20) of -11.81%, Distance from 50-Day Simple Moving Average of -14.79 percent and Distance from 200-Day Simple Moving Average of -19.6%.
The Company currently has ROA (Return on Assets) of 0.8 percent, Return on Equity (ROE) of 6.1 Percent and Return on Investment (ROI) of 11% with Gross margin of 0 percent and Operating & Profit margin of 78.5% and 21.7% respectively.